Top

Published in:

Open Access 01-12-2015 | NON-THEMATIC REVIEW

EPLIN: a fundamental actin regulator in cancer metastasis?

Authors: Ross J. Collins, Wen G. Jiang, Rachel Hargest, Malcolm D. Mason, Andrew J. Sanders

Published in: Cancer and Metastasis Reviews | Issue 4/2015

Abstract

Treatment of malignant disease is of paramount importance in modern medicine. In 2012, it was estimated that 162,000 people died from cancer in the UK which illustrates a fundamental problem. Traditional treatments for cancer have various drawbacks, and this creates a considerable need for specific, molecular targets to overcome cancer spread. Epithelial protein lost in neoplasm (EPLIN) is an actin-associated molecule which has been implicated in the development and progression of various cancers including breast, prostate, oesophageal and lung where EPLIN expression is frequently lost as the cancer progresses. EPLIN is important in the regulation of actin dynamics and has multiple associations at epithelial cells junctions. Thus, EPLIN loss in cancer may have significant effects on cancer cell migration and invasion, increasing metastatic potential. Overexpression of EPLIN has proved to be an effective tool for manipulating cancerous traits such as reducing cell growth and cell motility and rendering cells less invasive illustrating the therapeutic potential of EPLIN. Here, we review the current state of knowledge of EPLIN, highlighting EPLIN involvement in regulating cytoskeletal dynamics, signalling pathways and implications in cancer and metastasis.

Stewart, B., & Wild, C. (2014). World Cancer Report 2014.

CancerResearchUK (2015). Cancer stats: cancer statistics for the UK. http://www.cancerresearchuk.org/cancer-info/cancerstats/. Accessed 20th November 2014.

Chang, D. D., Park, N. H., Denny, C. T., Nelson, S. F., & Pe, M. (1998). Characterization of transformation related genes in oral cancer cells. Oncogene, 16(15), 1921–1930. doi:10.1038/sj.onc.1201715.CrossRefPubMed

Maul, R. S., & Chang, D. D. (1999). EPLIN, epithelial protein lost in neoplasm. Oncogene, 18(54), 7838–7841. doi:10.1038/sj.onc.1203206.CrossRefPubMed

Chen, S., Maul, R. S., Kim, H. R., & Chang, D. D. (2000). Characterization of the human EPLIN (Epithelial Protein Lost in Neoplasm) gene reveals distinct promoters for the two EPLIN isoforms. Gene, 248(1–2), 69–76.CrossRefPubMed

Brown, M. C., Perrotta, J. A., & Turner, C. E. (1996). Identification of LIM3 as the principal determinant of paxillin focal adhesion localization and characterization of a novel motif on paxillin directing vinculin and focal adhesion kinase binding. Journal of Cell Biology, 135(4), 1109–1123.CrossRefPubMed

Song, Y., Maul, R. S., Gerbin, C. S., & Chang, D. D. (2002). Inhibition of anchorage-independent growth of transformed NIH3T3 cells by epithelial protein lost in neoplasm (EPLIN) requires localization of EPLIN to actin cytoskeleton. Molecular Biology of the Cell, 13(4), 1408–1416. doi:10.1091/mbc.01-08-0414.PubMedCentralCrossRefPubMed

Maul, R. S., Sachi Gerbin, C., & Chang, D. D. (2001). Characterization of mouse epithelial protein lost in neoplasm (EPLIN) and comparison of mammalian and zebrafish EPLIN. Gene, 262(1–2), 155–160.CrossRefPubMed

Wang, H., Wang, H., Zhu, Z., Yang, S., Feng, S., & Li, K. (2007). Characterization of porcine EPLIN gene revealed distinct expression patterns for the two isoforms. Animal Biotechnology, 18(2), 101–108. doi:10.1080/10495390600864660.CrossRefPubMed

10.

Jiang, W. G., Martin, T. A., Lewis-Russell, J. M., Douglas-Jones, A., Ye, L., & Mansel, R. E. (2008). Eplin-alpha expression in human breast cancer, the impact on cellular migration and clinical outcome. Molecular Cancer, 7, 71. doi:10.1186/1476-4598-7-71.PubMedCentralCrossRefPubMed

11.

Liu, Y., Sanders, A. J., Zhang, L., & Jiang, W. G. (2012). EPLIN-alpha expression in human oesophageal cancer and its impact on cellular aggressiveness and clinical outcome. Anticancer Research, 32(4), 1283–1289.PubMed

12.

Sanders, A. J., Martin, T. A., Ye, L., Mason, M. D., & Jiang, W. G. (2011). EPLIN is a negative regulator of prostate cancer growth and invasion. Journal of Urology, 186(1), 295–301. doi:10.1016/j.juro.2011.03.038.CrossRefPubMed

13.

Sanders, A. J., Ye, L., Mason, M. D., & Jiang, W. G. (2010). The impact of EPLINalpha (Epithelial protein lost in neoplasm) on endothelial cells, angiogenesis and tumorigenesis. Angiogenesis, 13(4), 317–326. doi:10.1007/s10456-010-9188-7.CrossRefPubMed

14.

Liu, Y., Sanders, A. J., Zhang, L., & Jiang, W. G. (2012). Expression profile of Epithelial Protein Lost in Neoplasm-Alpha (EPLIN-α) in human pulmonary cancer and its impact on SKMES-1 cells in vitro. Journal of Cancer Therapy, 3, 452–459. doi:10.4236/jct.2012.324058.CrossRef

15.

Maul, R. S., Song, Y., Amann, K. J., Gerbin, S. C., Pollard, T. D., & Chang, D. D. (2003). EPLIN regulates actin dynamics by cross-linking and stabilizing filaments. Journal of Cell Biology, 160(3), 399–407. doi:10.1083/jcb.200212057.PubMedCentralCrossRefPubMed

16.

Tsurumi, H., Harita, Y., Kurihara, H., Kosako, H., Hayashi, K., Matsunaga, A., et al. (2014). Epithelial protein lost in neoplasm modulates platelet-derived growth factor-mediated adhesion and motility of mesangial cells. Kidney International, 86(3), 548–557. doi:10.1038/ki.2014.85.CrossRefPubMed

17.

Abe, K., & Takeichi, M. (2008). EPLIN mediates linkage of the cadherin catenin complex to F-actin and stabilizes the circumferential actin belt. Proceedings of the National Academy of Sciences of the United States of America, 105(1), 13–19. doi:10.1073/pnas.0710504105.PubMedCentralCrossRefPubMed

18.

Smith, T. C., Fang, Z., & Luna, E. J. (2010). Novel interactors and a role for supervillin in early cytokinesis. Cytoskeleton (Hoboken), 67(6), 346–364. doi:10.1002/cm.20449.

19.

Karakose, E., Geiger, T., Flynn, K., Lorenz-Baath, K., Zent, R., Mann, M., et al. (2015). The focal adhesion protein PINCH-1 associates with EPLIN at integrin adhesion sites. Journal of Cell Science, 128(5), 1023–1033. doi:10.1242/jcs.162545.CrossRefPubMed

20.

Han, M. Y., Kosako, H., Watanabe, T., & Hattori, S. (2007). Extracellular signal-regulated kinase/mitogen-activated protein kinase regulates actin organization and cell motility by phosphorylating the actin cross-linking protein EPLIN. Molecular and Cellular Biology, 27(23), 8190–8204. doi:10.1128/mcb.00661-07.PubMedCentralCrossRefPubMed

21.

Steder, M., Alla, V., Meier, C., Spitschak, A., Pahnke, J., Furst, K., et al. (2013). DNp73 exerts function in metastasis initiation by disconnecting the inhibitory role of EPLIN on IGF1R-AKT/STAT3 signaling. Cancer Cell, 24(4), 512–527. doi:10.1016/j.ccr.2013.08.023.CrossRefPubMed

22.

Seong, B. K., Lau, J., Adderley, T., Kee, L., Chaukos, D., Pienkowska, M., et al. (2014). SATB2 enhances migration and invasion in osteosarcoma by regulating genes involved in cytoskeletal organization. Oncogene. doi:10.1038/onc.2014.289.PubMedCentral

23.

Ohoka, A., Kajita, M., Ikenouchi, J., Yako, Y., Kitamoto, S., Kon, S., et al. (2015). EPLIN is a crucial regulator for extrusion of RasV12-transformed cells. Journal of Cell Science, 128(4), 781–789. doi:10.1242/jcs.163113.CrossRefPubMed

24.

Stricker, J., Falzone, T., & Gardel, M. L. (2010). Mechanics of the F-actin cytoskeleton. Journal of Biomechanics, 43(1), 9–14. doi:10.1016/j.jbiomech.2009.09.003.PubMedCentralCrossRefPubMed

25.

Leitner, L., Shaposhnikov, D., Descot, A., Hoffmann, R., & Posern, G. (2010). Epithelial Protein Lost in Neoplasm alpha (Eplin-alpha) is transcriptionally regulated by G-actin and MAL/MRTF coactivators. Molecular Cancer, 9, 60. doi:10.1186/1476-4598-9-60.PubMedCentralCrossRefPubMed

26.

Kim, J. S., Xu, X., Li, H., Solomon, D., Lane, W. S., Jin, T., et al. (2011). Mechanistic analysis of a DNA damage-induced, PTEN-dependent size checkpoint in human cells. Molecular and Cellular Biology, 31(13), 2756–2771. doi:10.1128/mcb.01323-10.PubMedCentralCrossRefPubMed

27.

Ratheesh, A., & Yap, A. S. (2012). A bigger picture: classical cadherins and the dynamic actin cytoskeleton. Nature Reviews Molecular Cell Biology, 13(10), 673–679. doi:10.1038/nrm3431.CrossRefPubMed

28.

Meng, W., & Takeichi, M. (2009). Adherens junction: molecular architecture and regulation. Cold Spring Harbor Perspectives in Biology, 1(6), a002899. doi:10.1101/cshperspect.a002899.PubMedCentralCrossRefPubMed

29.

Mege, R. M., Gavard, J., & Lambert, M. (2006). Regulation of cell-cell junctions by the cytoskeleton. Current Opinion in Cell Biology, 18(5), 541–548. doi:10.1016/j.ceb.2006.08.004.CrossRefPubMed

30.

Yonemura, S. (2011). Cadherin-actin interactions at adherens junctions. Current Opinion in Cell Biology, 23(5), 515–522. doi:10.1016/j.ceb.2011.07.001.CrossRefPubMed

31.

Nelson, W. J. (2008). Regulation of cell-cell adhesion by the cadherin-catenin complex. Biochemical Society Transactions, 36(Pt 2), 149–155. doi:10.1042/bst0360149.PubMedCentralCrossRefPubMed

32.

Drees, F., Pokutta, S., Yamada, S., Nelson, W. J., & Weis, W. I. (2005). Alpha-catenin is a molecular switch that binds E-cadherin-beta-catenin and regulates actin-filament assembly. Cell, 123(5), 903–915. doi:10.1016/j.cell.2005.09.021.PubMedCentralCrossRefPubMed

33.

Yamada, S., Pokutta, S., Drees, F., Weis, W. I., & Nelson, W. J. (2005). Deconstructing the cadherin-catenin-actin complex. Cell, 123(5), 889–901. doi:10.1016/j.cell.2005.09.020.PubMedCentralCrossRefPubMed

34.

Cavey, M., Rauzi, M., Lenne, P. F., & Lecuit, T. (2008). A two-tiered mechanism for stabilization and immobilization of E-cadherin. Nature, 453(7196), 751–756. doi:10.1038/nature06953.CrossRefPubMed

35.

Taguchi, K., Ishiuchi, T., & Takeichi, M. (2011). Mechanosensitive EPLIN-dependent remodeling of adherens junctions regulates epithelial reshaping. Journal of Cell Biology, 194(4), 643–656. doi:10.1083/jcb.201104124.PubMedCentralCrossRefPubMed

36.

Geiger, B., Tokuyasu, K. T., Dutton, A. H., & Singer, S. J. (1980). Vinculin, an intracellular protein localized at specialized sites where microfilament bundles terminate at cell membranes. Proceedings of the National Academy of Sciences of the United States of America, 77(7), 4127–4131.PubMedCentralCrossRefPubMed

37.

Sawyer, J. K., Harris, N. J., Slep, K. C., Gaul, U., & Peifer, M. (2009). The Drosophila afadin homologue Canoe regulates linkage of the actin cytoskeleton to adherens junctions during apical constriction. Journal of Cell Biology, 186(1), 57–73. doi:10.1083/jcb.200904001.PubMedCentralCrossRefPubMed

38.

Chervin-Petinot, A., Courcon, M., Almagro, S., Nicolas, A., Grichine, A., Grunwald, D., et al. (2012). Epithelial protein lost in neoplasm (EPLIN) interacts with alpha-catenin and actin filaments in endothelial cells and stabilizes vascular capillary network in vitro. Journal of Biological Chemistry, 287(10), 7556–7572. doi:10.1074/jbc.M111.328682.PubMedCentralCrossRefPubMed

39.

Gulino-Debrac, D. (2013). Mechanotransduction at the basis of endothelial barrier function. Tissue Barriers, 1(2), e24180. doi:10.4161/tisb.24180.PubMedCentralCrossRefPubMed

40.

Heng, Y. W., & Koh, C. G. (2010). Actin cytoskeleton dynamics and the cell division cycle. International Journal of Biochemistry and Cell Biology, 42(10), 1622–1633. doi:10.1016/j.biocel.2010.04.007.CrossRefPubMed

41.

Chircop, M., Oakes, V., Graham, M. E., Ma, M. P., Smith, C. M., Robinson, P. J., et al. (2009). The actin-binding and bundling protein, EPLIN, is required for cytokinesis. Cell Cycle, 8(5), 757–764.CrossRefPubMed

42.

Pribic, J., & Brazill, D. (2012). Paxillin phosphorylation and complexing with Erk and FAK are regulated by PLD activity in MDA-MB-231 cells. Cellular Signalling, 24(8), 1531–1540. doi:10.1016/j.cellsig.2012.03.015.PubMedCentralCrossRefPubMed

43.

Pearson, L. L., Castle, B. E., & Kehry, M. R. (2001). CD40-mediated signaling in monocytic cells: up-regulation of tumor necrosis factor receptor-associated factor mRNAs and activation of mitogen-activated protein kinase signaling pathways. International Immunology, 13(3), 273–283.CrossRefPubMed

44.

Zhang, S., Wang, X., Iqbal, S., Wang, Y., Osunkoya, A. O., Chen, Z., et al. (2013). Epidermal growth factor promotes protein degradation of epithelial protein lost in neoplasm (EPLIN), a putative metastasis suppressor, during epithelial-mesenchymal transition. Journal of Biological Chemistry, 288(3), 1469–1479. doi:10.1074/jbc.M112.438341.PubMedCentralCrossRefPubMed

45.

Kalluri, R., & Weinberg, R. A. (2009). The basics of epithelial-mesenchymal transition. Journal of Clinical Investigation, 119(6), 1420–1428. doi:10.1172/jci39104.PubMedCentralCrossRefPubMed

46.

Lamouille, S., Xu, J., & Derynck, R. (2014). Molecular mechanisms of epithelial-mesenchymal transition. Nature Reviews Molecular Cell Biology, 15(3), 178–196. doi:10.1038/nrm3758.PubMedCentralCrossRefPubMed

47.

Zhang, S., Wang, X., Osunkoya, A. O., Iqbal, S., Wang, Y., Chen, Z., et al. (2011). EPLIN downregulation promotes epithelial-mesenchymal transition in prostate cancer cells and correlates with clinical lymph node metastasis. Oncogene, 30(50), 4941–4952. doi:10.1038/onc.2011.199.PubMedCentralCrossRefPubMed

Title: EPLIN: a fundamental actin regulator in cancer metastasis?
Authors: Ross J. Collins
Wen G. Jiang
Rachel Hargest
Malcolm D. Mason
Andrew J. Sanders
Publication date: 01-12-2015
Publisher: Springer US
Published in: Cancer and Metastasis Reviews / Issue 4/2015
Print ISSN: 0167-7659
Electronic ISSN: 1573-7233
DOI: https://doi.org/10.1007/s10555-015-9595-8

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras

Prof. Fabrice Barlesi

Developed by: Springer Medicine

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 4/2015

New advances in ovarian autotransplantation to restore fertility in cancer patients

Genetically engineered mucin mouse models for inflammation and cancer

Retinoblastoma: might photodynamic therapy be an option?

Tumor cell survival pathways activated by photodynamic therapy: a molecular basis for pharmacological inhibition strategies

Tetraspanin CD82: a suppressor of solid tumors and a modulator of membrane heterogeneity

Neutrophils: important contributors to tumor progression and metastasis

Keynote webinar | Spotlight on antibody–drug conjugates in cancer